Vaxcyte, Inc. $PCVX Holdings Boosted by Comerica Bank

Key Points

• Comerica Bank increased its holdings in Vaxcyte, Inc. by 6.2% after purchasing 21,091 shares, bringing its total ownership to 360,186 shares valued at approximately $13.6 million.
• Vaxcyte's stock has a current market capitalization of $3.95 billion, with a 52-week range between $27.66 and $121.06, indicating significant volatility.
• Analysts maintain a consensus "Buy" rating for Vaxcyte, with a price target averaging $136.50, despite the company reporting a larger-than-expected loss in its latest quarter.

Comerica Bank raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 6.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 360,186 shares of the company's stock after buying an additional 21,091 shares during the quarter. Comerica Bank owned approximately 0.28% of Vaxcyte worth $13,601,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in Vaxcyte by 5.5% in the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after acquiring an additional 9,416 shares during the period. PNC Financial Services Group Inc. increased its position in Vaxcyte by 5.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock valued at $362,000 after acquiring an additional 524 shares during the period. Parallel Advisors LLC increased its position in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares during the period. Envestnet Asset Management Inc. increased its position in Vaxcyte by 75.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company's stock valued at $3,648,000 after acquiring an additional 41,517 shares during the period. Finally, Deutsche Bank AG boosted its holdings in shares of Vaxcyte by 5.6% in the fourth quarter. Deutsche Bank AG now owns 1,212,706 shares of the company's stock valued at $99,272,000 after acquiring an additional 64,522 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cowen reiterated a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Performance

NASDAQ PCVX traded up $0.02 on Friday, reaching $30.79. The company's stock had a trading volume of 944,896 shares, compared to its average volume of 1,519,997. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The stock has a market cap of $4.00 billion, a PE ratio of -7.49 and a beta of 1.21. The firm's 50 day moving average is $33.34 and its two-hundred day moving average is $42.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business earned ($1.10) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.